Kann ich es bekommen?
Ja, wenn ein Arzt entscheidet, dass es für Sie geeignet ist. Alprostadil ist in der EU zugelassen und kann nach einer ärztlichen Prüfung verschrieben werden.
AlprostadilRezeptpflichtig
Ärztliche Online-Beratung für Alprostadil.
Ein in der EU zugelassener Arzt prüft Ihren Fall und stellt, falls Sie geeignet sind, ein elektronisches Rezept aus, das in jeder EU-Apotheke gemäß der Richtlinie 2011/24/EU gültig ist.
- A non-PDE5 route
- Direct, local action
- An option when oral PDE5s don't work or aren't allowed
Beratung startenBeratung starten · 35 €
Volle Rückerstattung, wenn eine Prüfung abgelehnt wird · Das Medikament wird, falls verschrieben, separat in einer Apotheke abgegeben und bezahlt.
IN EINFACHEN WORTEN
Was Alprostadil ist und wie Sie eine Behandlung erhalten
Alprostadil ist eine Nachbildung von Prostaglandin E1, einem körpereigenen Stoff, der Blutgefäße erweitert. Anders als die Tabletten wird es direkt am Penis angewendet: als Creme auf der Spitze, als Spritze in die Seite des Schafts oder als kleines Pellet in der Harnröhre. So wirkt es direkt auf die Blutgefäße. Es ist in EU-Ländern seit 1994 als Spritze und seit 2014 als Creme gegen Erektionsstörungen zugelassen. Da es örtlich wirkt, treten auch die wichtigsten Nebenwirkungen vor Ort auf: Brennen, Schmerzen oder Rötung an der Anwendungsstelle und selten eine zu lange anhaltende Erektion, die dringend ärztlich behandelt werden muss.
Alprostadil ist seit 29. November 1994 für die Anwendung in der EU zugelassen. Ein zugelassener Arzt kann es Ihnen daher verschreiben, wenn es medizinisch für Sie geeignet ist.
Was kann ich stattdessen nehmen?
Unsere Ärzte prüfen alle Optionen für Sexuelle Gesundheit und empfehlen, was zu Ihrer Krankengeschichte und Ihren Zielen passt.
Alle Optionen für Sexuelle Gesundheit ansehenWas zeigen die Studien?
Alle Studien zu Alprostadil sind unten aufgeführt: mit der Anzahl der Teilnehmenden und der Angabe, ob die Ergebnisse von Fachleuten geprüft wurden oder nur aus einer Mitteilung des Unternehmens stammen.
Zu den StudienGEPRÜFTE EVIDENZ
Alprostadil: Evidenz- und Zulassungsleitfaden.
WAS ES IST
Wie es wirkt
Alprostadil is a man-made copy of a natural body chemical (prostaglandin E1) that is applied to or injected into the penis, where it widens the blood vessels directly so blood flows in.
ENTWICKLUNGSSTAND
EU-zugelassenes Arzneimittel
Studienregister4 registrierte Studien
Jede NCT-Kennung führt zum Eintrag bei ClinicalTrials.gov. Eine Ergebnismeldung ist nicht dasselbe wie eine begutachtete Veröffentlichung.
| STUDIE / NCT | BEVÖLKERUNG | TEILNEHMENDE | STATUS | ERGEBNIS / ABSCHLUSS |
|---|---|---|---|---|
| Integrated analysis of two multicentre, double-blind, parallel-group topical-cream studies | Men with an IIEF erectile function domain score of 25 or less, including men with diabetes and men taking organic nitrates | 1,732 | Ausgewertet | 2006-08-01 |
| Alprostadil Study Group — intracavernosal dose-response study | Men with erectile dysfunction of vasculogenic, neurogenic, psychogenic and mixed causes | 296 | Ausgewertet | 1996-04-04 |
| Alprostadil Study Group — six-month intracavernosal self-injection study | Men with erectile dysfunction of mixed causes | 683 | Ausgewertet | 1996-04-04 |
| MUSE Study Group — transurethral alprostadil, double-blind placebo-controlled trial | Men aged 27-88 with chronic erectile dysfunction from various organic causes | 1,511 | Ausgewertet | 1997-01-02 |
Was die Studien berichteten
Die Ergebnisse sind nach Quelle und Evidenzgrad getrennt, damit Fachpublikationen nicht mit Herstellerangaben verwechselt werden.
Fachbegutachtet
Padma-Nathan H, Yeager JL. An integrated analysis of alprostadil topical cream for the treatment of erectile dysfunction in 1732 patients. Urology 2006;68(2):386-391. doi:10.1016/j.urology.2006.02.027 (PMID 16904458)| DOSIS ODER GRUPPE | MITTLERE GEWICHTSÄNDERUNG | WOCHEN |
|---|---|---|
| 100 microgram cream (n=434) | IIEF erectile function domain change from baseline +1.6 points vs -0.7 on placebo (p<0.001) | 12 |
| 200 microgram cream (n=430) | IIEF erectile function domain change from baseline +2.5 points vs -0.7 on placebo (p<0.001) | 12 |
| 300 microgram cream (n=434) | IIEF erectile function domain change from baseline +2.4 points vs -0.7 on placebo (p<0.001) | 12 |
The IIEF changes are small in absolute terms and the authors describe the SEP2 and SEP3 improvements as slight though statistically significant; the studies ran for 12 weeks and cover the topical cream only, not the injected or intraurethral forms.
Quellen
Zuletzt geprüft 2026-07-27
- AEMPS CIMA — Caverject 20 microgramos (alprostadil, intracavernosal injection), reg. 60535, first authorised in Spain 29 November 1994, indicated for erectile dysfunction
- AEMPS CIMA — Virirec 3 mg/g crema (alprostadil topical), reg. 78357, first authorised April 2014; the same cream was approved via the EU decentralised procedure as Vitaros in 2013
- Urology 2006 — Integrated analysis of alprostadil topical cream in 1,732 patients (PMID 16904458)
- N Engl J Med 1996 — Efficacy and safety of intracavernosal alprostadil (PMID 8596569)
- N Engl J Med 1997 — Treatment of men with erectile dysfunction with transurethral alprostadil, MUSE Study Group (PMID 8970933)
BENANNTE SICHERHEITSSIGNALE
Was bei Alprostadil berichtet wurde.
Application-site burning, penile pain and redness (cream)
Penile burning, penile pain, penile erythema, genital pain and genital discomfort are all listed as common in the EU product information for alprostadil 3 mg/g cream. In the clinical trial the withdrawal rate was 30% in the 300 microgram group compared with 20% in the 200 microgram group.
Injection-site pain (intracavernosal)
Penile pain is listed as very common in the EU product information for alprostadil injection. In the six-month self-injection study, usually mild penile pain occurred in 50% of men at some time but after only 11% of injections.
Prolonged erection and priapism (intracavernosal)
In the EU product information for alprostadil injection, a prolonged erection lasting 4 to 6 hours developed in 4% of patients and priapism (a painful erection lasting more than 6 hours) in 0.4%. In the six-month self-injection study, prolonged erections occurred in 5% of men and priapism in 1%.
Prolonged erection and priapism (cream)
Listed as uncommon in the EU product information for alprostadil cream. Priapism was seen in 1 patient (0.06%) across the two 3-month studies and in 5 patients (0.4%) in the study lasting more than 6 months. An erection lasting more than 4 hours needs immediate medical help, because untreated priapism can permanently damage erectile tissue.
Penile fibrosis (intracavernosal)
Penile fibrosis, including angulation, fibrotic nodules and Peyronie's disease, was reported in 3% of clinical-trial patients in the EU product information for alprostadil injection, rising to about 8% in a self-administration study of up to 18 months. Injection-site haematoma was reported by 3% and bruising by 2%.
Dizziness and fainting
In the phase 3 cream studies, symptomatic low blood pressure (dizziness) and fainting occurred in 0.4%, 0.4% and 0.5% of patients on the 100, 200 and 300 microgram doses. Patients are advised not to drive or do hazardous tasks until they know how they react.
Effects on a female partner
Vulvovaginal burning and vaginitis are listed as common reactions in female partners in the EU product information for alprostadil cream.
Penile pain (intraurethral)
In the transurethral pivotal trial, mild penile pain was the most common side effect, occurring after 10.8% of treatments; in-clinic low blood pressure occurred in 3.3% of men, and no man had priapism or penile fibrosis.
DarreichungsformHarnröhrencreme oder Injektion
HäufigkeitBei Bedarf
ErgebnisseDirect local action
Was Sie an Hi-Doctor zahlen35 € einmalig
IN 60 SEKUNDEN
Alprostadil auf einen Blick
- A prostaglandin E1 medicine that widens the blood vessels inside the penis
- Adult men whose erectile dysfunction is unsuited to, or not helped by, oral tablets
- Given as a cream at the tip of the penis, a urethral pellet, or an injection
- An erection lasting 4 hours or more is priapism, and it is a medical emergency
- Hi-Doctor consultation fee; the medicine is paid separately at a pharmacy
Überblick
Was ist Alprostadil?
Wird auch als Caverject, MUSE, Vitaros vertrieben.
Wirkstoff: Alprostadil · Dosierungen: Cream 3 mg/g on demand
Alprostadil is a prostaglandin E1 that directly dilates the blood vessels of the penis. It's considered when oral PDE5 inhibitors are ineffective or contraindicated.
It's administered as a urethral cream or an intracavernous injection, under medical instruction — each route has its own efficacy and tolerability profile. Correct technique matters, and the doctor explains the protocol and the warning signs.
SO WIRKT ES
Was Alprostadil in Ihrem Körper bewirkt
Rather than blocking an enzyme, alprostadil acts directly on the penile blood vessels, dilating them locally — no PDE5 pathway involved, so it can work where oral options don't.
A copy of prostaglandin E1
Alprostadil is chemically identical to prostaglandin E1, a signalling substance the body already makes. It is not swallowed. It is placed into or onto the penis itself, so it acts on the erectile tissue at the site rather than circulating through the whole body first.
Cavernosal muscle relaxes
The drug relaxes the smooth muscle of the corpora cavernosa, the two spongy cylinders that run the length of the penis, and widens the cavernosal arteries feeding them. Blood flow into the erectile tissue rises, and that increase in flow is what produces rigidity.
It does not need arousal
Because it acts on the tissue directly, alprostadil does not depend on the nitric oxide signal that sexual stimulation produces. In clinic testing it created erections on its own. That is the core difference from tablets, and it is also why an erection can outlast the encounter.
Wie es hilft
How it helps.
A different pathway
Works directly on the blood vessels — not through the PDE5 enzyme.
Local application
Applied where it acts, shortly before intercourse.
Guided by your doctor
Administration technique and warning signs are explained before you start.
Was Sie erwartet
How to use it.
Prescribed with clear administration instructions. Your doctor explains the protocol, and follow-up happens through your account chat.
- Prescribed with clear administration instructions
- Applied shortly before intercourse
- Correct technique matters — your doctor explains it
- Follow-up and questions through your account chat
Forms your doctor can prescribe
- Urethral cream3 mg/g — on demand
Ihr Behandlungsplan ist individuell
Diese Schritte sind nur Richtwerte. Ihr Arzt passt den Plan daran an, wie Sie ansprechen und das Medikament vertragen — und Sie können ihm jederzeit schreiben.
IM ALLTAG
Alprostadil im Alltag anwenden
Get shown the technique first
Every form of alprostadil has to be demonstrated by a medical professional before you use it yourself. For the injection and the urethral pellet the first doses are given or supervised in a clinic, not at home, and that step cannot be skipped.
Empty your bladder first
Urinate before using the cream or the pellet. A moist urethra helps the medicine dissolve and spread. Do not urinate straight after the cream, because the dose can be washed out before it has had time to work.
Cream sits at the opening
Roll the single-dose container between your hands to warm it, hold the penis upright and squeeze the tip to widen the opening. Place the container at the opening without inserting it, push all the cream in, then hold the penis upright for about 30 seconds.
Pellet needs a stretch and roll
For the urethral pellet, stretch the penis upward to its full length, insert the applicator, press the button and withdraw it. Then roll the penis between your hands for at least 10 seconds so the medicine coats the urethral wall.
Stand or walk for ten minutes
After the pellet, sit or preferably stand or walk for about 10 minutes while the erection develops. An erection usually appears 5 to 10 minutes after the pellet and lasts roughly 30 to 60 minutes. The cream works in 5 to 30 minutes.
Injections rotate side and site
The injection goes into the upper side of the penis, along the third nearest the body, avoiding visible veins. Change both the side and the exact spot each time. Never straighten or reuse a bent needle, because needles can break.
Use a condom if pregnancy is possible
A condom is required if your partner is pregnant or could become pregnant, and it also reduces vaginal irritation, which is a reported reaction. Only latex condoms have been tested with the cream. Alprostadil is not a contraceptive and does not prevent infection.
Respect the frequency limits
The cream is used at most 2 to 3 times a week and once in 24 hours. Injections are at most once a day and three times a week. The pellet is at most 2 doses in 24 hours and 7 in 7 days.
Sicherheit zuerst
Sicherheit, vollständig.
Alprostadil ist ein wirksames Medikament — und wie jedes Medikament birgt es Risiken. Ihr Arzt prüft all dies vor der Verschreibung. Hier ist das ehrliche Bild, nicht nur Beruhigung.
Nebenwirkungen, nach Häufigkeit
Stop and get urgent medical help if
seek medical help immediately
these need urgent attention, whatever the frequency
- An erection lasts 4 hours or more, which is priapism and a medical emergency that must not be left more than 6 hours
- Penile pain will not settle, or you notice a new bend, lump or hard patch in the penis
- You faint, feel close to fainting, or go dizzy with a sudden drop in blood pressure after a dose
- You get chest pain, or sudden weakness, numbness or trouble speaking
- Bleeding from the urethra will not stop, or there is blood in your urine
- Hives, a spreading rash or swelling appear, which can signal an allergic reaction
- A needle breaks and a fragment stays in the penis, which has needed surgical removal
Very common
very common (≥1/10)
more than 1 in 10 people
- Penile pain after intracavernosal injection, reported at least once by 30% of men and after 11% of injections
- Penile pain after the urethral pellet, in most cases rated mild or moderate
- Burning in the urethra after the urethral pellet
Common
common (≥1/100 to <1/10)
somewhere between 1 in 100 and 1 in 10 people
- Burning, tingling, throbbing or numbness in the penis, with the cream
- Redness, swelling, itching or general discomfort of the penis or genitals, with the cream
- Urethral pain with the cream, or minor urethral bleeding with the pellet
- An erection stronger or longer than expected, listed for all three forms
- Peyronie's disease, penile fibrosis, angulation or fibrotic nodules, with the injection and the pellet
- Bruising or a collection of blood at the injection site
- Headache, dizziness, symptomatic low blood pressure and muscle spasms, with the pellet
- Vaginal burning or itching in the partner, reported by about 6% of partners in the pellet studies
- Skin rash, with the cream
- Balanitis, inflammation of the head of the penis, with the cream
Uncommon
uncommon (≥1/1,000 to <1/100)
somewhere between 1 in 1,000 and 1 in 100 people
- Prolonged erection or priapism, listed at this frequency for all three forms
- Dizziness, fainting or a fall in blood pressure, listed for all three forms
- Painful erection, excessive rigidity, or loss of sensation in the penis
- Narrowing of the urethra, or inflammation of the urinary tract, with the cream
- Painful or frequent urination, urgency, blood in the urine or urethral bleeding
- Testicular or scrotal pain, swelling, redness or a lump, and pelvic or perineal pain
- Phimosis, ejaculation problems, or erectile dysfunction reported as a reaction
- Nausea, dry mouth, sweating, itching, rash, redness or a faster heartbeat
- Itching of the vulva or vagina in the partner, with the cream
- Widened pupils, extra heartbeats, a raised blood creatinine reading, or feeling weak
Rare
rare (≥1/10,000 to <1/1,000)
somewhere between 1 in 10,000 and 1 in 1,000 people
- Urinary tract infection, listed at this frequency for the urethral pellet
- Penile fibrosis, listed at this frequency for the urethral pellet
Very rare
very rare (<1/10,000)
fewer than 1 in 10,000 people
- Hives, known medically as urticaria, listed at this frequency for the urethral pellet
Frequency not known
not known (cannot be estimated from the available data)
reported after launch, but too rarely counted to put a number on
- Stroke, recorded in the injection product information as cerebrovascular accident
- Reduced blood supply to the heart muscle, recorded as myocardial ischaemia
Erektionsstörungen bei erwachsenen Männern, als lokale Alternative zu Tabletten.
- Tragen Sie die Einmaldosis 5–30 Minuten vor dem Sex auf die Öffnung an der Penisspitze auf und folgen Sie der Technik in der Packungsbeilage.
- Die Wirkung hält etwa 1–2 Stunden an.
- Höchstens eine Dosis pro 24 Stunden und nicht mehr als 2–3 Dosen pro Woche.
- Waschen Sie sich nach dem Auftragen die Hände.
WER ES NICHT EINNEHMEN DARF UND WER BESONDERE VORSICHT BRAUCHT
- You have sickle-cell disease or sickle-cell trait, multiple myeloma or leukaemia, all of which predispose to priapism
- You have another condition predisposing to priapism, such as thrombocythaemia, polycythaemia, a tendency to venous thrombosis, a hyperviscosity syndrome, or past recurrent priapism
- You have a penile implant
- Your penis is anatomically deformed, including angulation, curvature, cavernosal fibrosis, Peyronie's disease or severe hypospadias
- You have urethritis or balanitis, or for the pellet a narrowing of the lower urethra
- You are allergic to alprostadil or to any other ingredient in the product
- A doctor has advised that sexual activity is inadvisable, for example with severe heart disease or unstable heart or circulation problems
- You have orthostatic hypotension, or a history of heart attack or fainting, which rule out the cream
- Your partner is pregnant or could become pregnant and a condom will not be used
- You are already using another erectile dysfunction treatment, including a PDE5 inhibitor tablet or another injected agent
Wann Sie dringend Hilfe suchen sollten
Bei schweren, plötzlichen oder unerwarteten Symptomen rufen Sie den örtlichen Notruf an oder suchen Sie die nächste Notaufnahme auf. Informieren Sie danach Ihren Arzt über den Chat Ihres Kontos.
Arzneimittel und Substanzen mit Wechselwirkungen
| ARZNEIMITTEL ODER SUBSTANZ | WAS PASSIEREN KANN | WAS DIE ÄRZTIN ODER DER ARZT TUT |
|---|---|---|
| PDE5 inhibitor tablets (sildenafil, tadalafil, vardenafil) | Never studied together; both act on blood vessels, so cardiovascular risk could add up | Not used together; the prescriber keeps you on one treatment at a time |
| Other injected erection agents (papaverine, phentolamine, thymoxamine) | Raises the risk of priapism, a painful prolonged abnormal erection | Not combined; alprostadil is prescribed on its own |
| Blood pressure medicines and other vasodilators | Blood pressure can fall further, and the risk is higher in older men | Prescribed with caution, with clear warning about dizziness and fainting |
| Anticoagulants and antiplatelet drugs (warfarin, heparin) | More bleeding after an injection, and more urethral bleeding or blood in the urine | Prescriber weighs the bleeding risk and may rule out the injected route |
| Sympathomimetics, decongestants and appetite suppressants | May reduce the effect of alprostadil, so a working dose can seem to fail | Prescriber reviews the full medicine list before changing any dose |
| Latex condoms | Only latex has been tested with the cream; other materials may be damaged by it | Use a latex condom, which is required anyway if a partner could be pregnant |
Ihren Fall ärztlich prüfen lassenGenau das prüft die Ärztin oder der Arzt, bevor überhaupt etwas verordnet wird.
Vollständige Sicherheitsübersicht zu Alprostadil lesenEVIDENZ
Was die klinischen Studien ergaben
In the two New England Journal of Medicine programmes that registered these products, the MUSE Study Group trial of the urethral pellet and the Alprostadil Study Group trials of intracavernosal injection, both routes produced erections firm enough for intercourse in most men who had first responded to a supervised test dose.
1,511 men aged 27 to 88 with chronic erectile dysfunction of organic cause · single clinic visit, up to four test doses
Transurethral alprostadil tested at 125, 250, 500 and 1000 micrograms
Quelle: Treatment of men with erectile dysfunction with transurethral alprostadil (MUSE Study Group)961 in-clinic responders who reported at least one home treatment · 3 months of home use
Transurethral alprostadil versus placebo, p<0.001; on average 7 of 10 doses were followed by intercourse
Quelle: Treatment of men with erectile dysfunction with transurethral alprostadil (MUSE Study Group)683 men in a self-injection study of intracavernosal alprostadil · 6 months
Patients and partners rated the activity satisfactory after 87% and 86% of injections
Quelle: Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction (Alprostadil Study Group)the same 1,511-man transurethral alprostadil programme · clinic testing plus 3 months at home
The most common side effect; no man in that study had priapism or penile fibrosis
Quelle: Treatment of men with erectile dysfunction with transurethral alprostadil (MUSE Study Group)men across three multicentre intracavernosal alprostadil studies · up to 6 months of self-injection
Alongside prolonged erection in 5% and penile pain in 50% of men, after 11% of injections
Quelle: Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction (Alprostadil Study Group)These are group averages from trials, not a forecast for any one person. Both routes were screened in clinic first, and the home figures describe only the men who had already responded to that supervised test dose, so they read better than the result an unselected group would get. The European Association of Urology also records that 41% to 68% of men stop intracavernous injections, most within the first two to three months, and that only about 30% stay on the urethral pellet long term, which is a fair reminder that tolerating a treatment matters as much as its measured efficacy.
ALTERNATIVEN
Alprostadil vs the oral tablets usually tried first
| ARZNEIMITTEL | ANWENDUNGSFORM | WIE OFT | ÜBLICHER DOSISBEREICH | IN DER EU ZUGELASSENE INDIKATION | WICHTIGSTE EVIDENZ |
|---|---|---|---|---|---|
| Sildenafil | Tablette zum Einnehmen | Bei Bedarf, maximal einmal täglich | 25–100 mg | Erectile dysfunction in adult men; sexual stimulation is required | Dose-response study: improved erections 56%, 77%, 84% vs 25% placebo |
| Tadalafil | Tablette zum Einnehmen | Bei Bedarf oder 5 mg einmal täglich | 2.5–20 mg | Erectile dysfunction in adult males; sexual stimulation is required | Dose-response study: improved erections 67% and 81% vs 35% placebo |
| Vardenafil | Tablette zum Einnehmen | Bei Bedarf, maximal einmal täglich | 5–20 mg | Erectile dysfunction in adult men; sexual stimulation is required | Dose-response study: improved erections 66%, 76%, 80% vs 30% placebo |
Unsicher, was zu Ihnen passt? Die Ärztin oder der Arzt prüft Ihre Vorgeschichte und sagt es Ihnen.
Beratung starten · 35 €ZUGANG UND KOSTEN
Alprostadil erhalten und was es kostet
Alprostadil is prescription-only in every EU country and no form of it is sold over the counter anywhere. Which form you can actually obtain varies a lot, so each row was read off that country's own medicines register rather than inferred from the EU-wide picture. The registers do not all publish the same thing: Spain, Portugal and Belgium record a marketing status per product, so those rows describe what is genuinely on sale, while Germany and Austria publish only whether an authorisation is currently valid, so their rows describe which forms are registered rather than which a pharmacy is stocking this week. Poland registers no alprostadil product for erectile dysfunction at all. The linked database is the current authority in every case.
Was Sie an Hi-Doctor zahlen
35 € einmalig
Beantworten Sie einige Fragen und ein in der EU zugelassener Arzt prüft Ihren Fall in durchschnittlich weniger als 2 Stunden. Volle Rückerstattung, falls es nicht das Richtige für Sie ist.
Was die Apotheke berechnet
Hi-Doctor verkauft, lagert und gibt keine Arzneimittel ab und legt deren Preis nicht fest. Das Arzneimittel wird separat in der Apotheke bezahlt; der Betrag hängt vom Land, der Packungsgröße, der Verfügbarkeit eines Generikums und der Kostenübernahme ab. Die in der Tabelle verlinkte offizielle Datenbank veröffentlicht den aktuellen zugelassenen Preis.
| LAND | ABGABESTATUS | VON DER KRANKENKASSE ÜBERNOMMEN? | OFFIZIELLE QUELLE |
|---|---|---|---|
| Spanien | Verschreibungspflichtig; die Injektion unterliegt einer Krankenhausdiagnose-Einschränkung | See national criteria | AEMPS CIMA |
Weitere Länder anzeigen
| Deutschland | Verschreibungspflichtig; Injektion, Harnröhrenstift und Creme sind alle zugelassen | Excluded from statutory health insurance | PharmNet.Bund AMIce |
|---|---|---|---|
| Frankreich | Verschreibungspflichtig; die Injektionen sind Liste I | Restricted — only for the organic causes listed in the official decision | Base de données publique des médicaments |
| Italien | Verschreibungspflichtig; ein Facharzt-Behandlungsplan wird für die Kostenübernahme benötigt | Restricted — AIFA Nota 75, intracavernosal injection only | AIFA Medicinali |
| Niederlande | Verschreibungspflichtig | See national criteria | CBG-MEB Geneesmiddeleninformatiebank |
| Portugal | Verschreibungspflichtig (MSRM); die Injektion und die Creme sind jeweils vermarktet | See national criteria | INFARMED Infomed |
| Belgien | Verschreibungspflichtig; Injektion und Creme sind kommerzialisiert, der Zweikammer-Kartusche nicht | See national criteria | FAGG-AFMPS medicines database |
| Irland | Verschreibungspflichtig | See national criteria | HPRA Find a Medicine |
| Österreich | Verschreibungspflichtig (Rp); der Harnröhrenstift ist als vermarktet gemeldet, Injektion und Creme als zugelassen | See national criteria | BASG Medikamente Info Austria |
| Polen | Nicht im Handel | — | Rejestr Produktów Leczniczych |
PREISE
Sie zahlen nur, wenn die Behandlung genehmigt wird.
35 € für eine Beratung zur sexuellen Gesundheit. Einmalige Zahlung ohne Folgekosten.
Sexuelle Gesundheit
EINMALIG
35 € einmalig
Eine Beratung, ein Arzt, eine Entscheidung.
Nichts wird je öffentlich gespeichert
Beratung starten
Volle Rückerstattung, wenn eine Prüfung abgelehnt wird
WAS IST INBEGRIFFEN
- Beratung durch einen in der EU zugelassenen Arzt
- Elektronisches Rezept bei Genehmigung
- Volle Rückerstattung bei Ablehnung
Volle Rückerstattung, wenn eine Prüfung abgelehnt wird
Wird eine Prüfung nicht genehmigt, erstatten wir die Beratungsgebühr von 35 € vollständig.
Hinweis: Das Medikament, falls der Arzt es verschreibt, wird separat in der Apotheke zu dem von ihr festgelegten Preis bezahlt. Hi-Doctor verkauft keine Medikamente.
WIE DIE ÄRZTLICHE ENTSCHEIDUNG FÄLLT
Eine approbierte Ärztin oder ein Arzt prüft Ihren Fall, kein Algorithmus
Eine in der EU approbierte Ärztin oder ein Arzt liest Ihren Fragebogen und antwortet in durchschnittlich weniger als 2 Stunden.
Entscheidet die Ärztin oder der Arzt, dass eine Verordnung nicht sicher ist, wird die Gebühr vollständig erstattet.
Die Nachbetreuung läuft im privaten Chat in Ihrem Konto, DSGVO-konform. Kein WhatsApp, keine SMS.
HÄUFIG GESTELLTE FRAGEN
Fragen zu Alprostadil.
ANDERE SEXUELLE GESUNDHEIT-BEHANDLUNGEN
Entdecken Sie verwandte Behandlungen.
QUELLEN
Woher diese Informationen stammen
- 01
Vitaros 3 mg/g cream: Summary of Product Characteristics — electronic medicines compendium (emc), 2026
- 02
Caverject Dual Chamber 20 micrograms: Summary of Product Characteristics — electronic medicines compendium (emc), 2026
- 03
MUSE 500 microgramos bastoncillo uretral: Ficha Técnica — AEMPS, Spain, 2016
- 04
Treatment of men with erectile dysfunction with transurethral alprostadil (MUSE Study Group) — New England Journal of Medicine 336(1):1-7, 1997
- 05
Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction (Alprostadil Study Group) — New England Journal of Medicine 334(14):873-7, 1996
- 06
EAU Guidelines on Sexual and Reproductive Health, limited update March 2025 — European Association of Urology, 2025
- 07
Alprostadil: authorised medicines register (Caverject, Virirec and alprostadil cream marketed; MUSE authorised but not marketed) — AEMPS CIMA, Spain, 2026
- 08
Alprostadil: Vitaros 300 microgrammes cream and Edex 10/20 microgrammes marketed, liste I, restricted reimbursement — Base de données publique des médicaments, France, 2026
- 09
Alprostadil products authorised in Ireland: Caverject 10 and 20 micrograms, Vitaros 3 mg/g cream — medicines.ie, Irish medicines compendium, 2026
- 10
Register of medicinal products: no ATC G04BE01 alprostadil product registered for erectile dysfunction — Rejestr Produktów Leczniczych, Poland, 2026
- 11
Nota 75: reimbursement of alprostadil by intracavernosal injection limited to defined neurological criteria — AIFA, Gazzetta Ufficiale della Repubblica Italiana n. 7, 2017
- 12
§ 34 SGB V: medicines predominantly for erectile dysfunction excluded from statutory health insurance — Bundesministerium der Justiz, Germany, 2026
- 13
Regeling zorgverzekering: MUSE urethral stick 125 to 1000 micrograms listed on the Dutch medicines annex — Wetten.overheid.nl, Netherlands, 2026
- 14
Viagra (sildenafil): Summary of Product Characteristics, Annex I — European Medicines Agency, 2025
- 15
Cialis (tadalafil): Summary of Product Characteristics, Annex I — European Medicines Agency, 2025
- 16
Levitra (vardenafil): Summary of Product Characteristics, Annex I — European Medicines Agency, 2024
- 17
Alprostadil, human medicines with a currently valid German authorisation: Caverject and Caverject Impuls 10 and 20 micrograms (Pfizer Pharma GmbH plus parallel importers), Muse 500 and 1000 micrograms (Viatris Healthcare GmbH), Vitaros 300 micrograms/100 mg cream (The Simple Pharma Company Limited). The register publishes marketability, not whether a product is currently distributed. — BfArM AMIce, public part, via PharmNet.Bund, Germany, 2026
- 18
Alprostadilo: Caverject 0,01 and 0,02 mg/ml (Laboratórios Pfizer, Lda.) and Vitaros cream 0,3 mg/100 mg (Recordati Ireland Ltd.), each authorised with at least one marketed presentation — INFARMED Infomed, Portugal, 2026
- 19
Alprostadil: Caverject 10 and 20 micrograms and Vytaros 3 mg/g cream recorded as commercialised; Caverject Impuls 10 and 20 micrograms recorded as not commercialised — FAGG-AFMPS medicines database, Belgium, 2026
- 20
Alprostadil, ATC G04BE01: Muse 250, 500 and 1000 micrograms recorded as marketed; Caverject, Caverject Dual and Vitaros 3 mg/g cream authorised, with no marketing status published — BASG Medikamente Info Austria, Arzneispezialitätenregister, 2026
Geprüft vom medizinischen Team von Hi-Doctor · Zuletzt geprüft am 2026-07-27 · Nächste Prüfung fällig am 2027-07-27
Diese Seite bietet Informationen zu einem Arzneimittel. Sie ist weder eine Empfehlung zur Einnahme noch ein Ersatz für eine ärztliche Beratung. Nur eine approbierte Ärztin oder ein Arzt, die oder der Ihre Vorgeschichte geprüft hat, kann entscheiden, ob eine Behandlung für Sie geeignet ist.
Finden Sie heraus, ob es zu Ihnen passt
Prüfen Sie, ob Alprostadil für Sie geeignet ist.
Beantworten Sie einige Fragen und ein in der EU zugelassener Arzt prüft Ihren Fall in durchschnittlich weniger als 2 Stunden. Volle Rückerstattung, falls es nicht das Richtige für Sie ist.